Eton Pharmaceuticals Inc Revenue Growth Rates (ETON), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Eton Pharmaceuticals Inc   (NASDAQ: ETON)
 

ETON's Revenue Growth by Quarter and Year

Eton Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ETON Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 37.59
1st Quarter March 23.74
FY 61.33

ETONs Annual Revenue
Eton Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 79.74 millions
Eton Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 38.41 millions
Eton Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 31.06 millions
Eton Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 21.25 millions
Eton Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 21.83 millions




ETON Revenue second quarter 2026 Y/Y Growth Comment
Eton Pharmaceuticals Inc reported Revenue surge of 98.67% year on year in the second quarter 2026, to $ 37.59 millions, this is lower than Eton Pharmaceuticals Inc 's recent average Revenue surge of 502.3%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 61 other companies have achieved higher Revenue growth. While Eton Pharmaceuticals Inc ' s Revenue jump of 98.67% ranks overall at the positon no. 657 in the second quarter 2026.


ETON Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 77.08 % 62.71 % -9.76 %
3rd Quarter September - 112.23 % 60.94 % 98.76 %
2nd Quarter June 98.67 % 119.24 % -26.11 % 58.7 %
1st Quarter March 40.81 % 140.51 % 32.26 % 143.12 %
FY   - 107.55 % 23.74 % -

Financial Statements
Eton Pharmaceuticals Inc 's second quarter 2026 Revenue $ 37.59 millions ETON's Income Statement
Eton Pharmaceuticals Inc 's second quarter 2025 Revenue $ 18.92 millions Quarterly ETON's Income Statement


ETON Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 1.1 % 21.17 % 19.84 %
3rd Quarter September - 15.54 % 19.35 % -45.21 %
2nd Quarter June 58.34 % 12.22 % 23.11 % 120.38 %
1st Quarter March 7.42 % 35.1 % -8.6 % -37.65 %
FY (Year on Year)   - 107.55 % 23.74 % -


Back to ETON Growth rate Comparisons >> Back to ETON Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #62
Healthcare Sector #139
Overall #657

Revenue Y/Y Growth Statistics
High Average Low
6576.45 % 502.3 % -2.66 %
(Dec 31 2021)  
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #62
Healthcare Sector #139
Overall #657
Revenue Y/Y Growth Statistics
High Average Low
6576.45 % 502.3 % -2.66 %
(Dec 31 2021)  

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Eton Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
14587.65 % 588.48 % -100 %
(Mar 31 2021)  


ETON's II. Quarter Q/Q Revenue Comment
Eton Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue jump of 58.34% quarter on quarter, to $ 37.59 millions.

Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the 12.22% growth in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Eton Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 211.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #60
Overall #211
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #60
Overall #211
Revenue Q/Q Growth Statistics
High Average Low
14587.65 % 588.48 % -100 %
(Mar 31 2021)  


ETON's II. Quarter Q/Q Revenue Comment
Eton Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue jump of 58.34% quarter on quarter, to $ 37.59 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 12.22% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Eton Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 211.


Eton Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 105.28 $ 86.61 $ 79.74 $ 70.12 $ 58.56
Y / Y Revenue Growth (TTM) 79.77 % 79.46 % 107.6 % 108.64 % 97.13 %
Year on Year Revenue Growth Overall Ranking # 351 # 266 # 442 # 1155 # 1244
Seqeuential Revenue Change (TTM) 21.55 % 8.62 % 13.73 % 19.73 % 21.34 %
Seq. Revenue Growth (TTM) Overall Ranking # 657 # 515 # 781 # 651 # 1960


Cumulative Revenue growth Comment
Although Eton Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 502.3% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 79.77% year on year, from 79.46% in Mar 31 2026.

In the Healthcare sector 94 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 266 to 351.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 62
Healthcare Sector # 95
Overall # 351

Revenue TTM Y/Y Growth Statistics
High Average Low
6576.45 %
 502.3 %
-2.66 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 62
Sector # 139
S&P 500 # 657
Cumulative Revenue growth Comment
Although Eton Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 502.3% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 79.77% year on year, from 79.46% in Mar 31 2026.

In the Healthcare sector 94 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 266 to 351.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 62
Healthcare Sector # 95
Overall # 351

Revenue TTM Y/Y Growth Statistics
High Average Low
6576.45 %
502.3 %
-2.66 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 62
Sector # 139
S&P 500 # 657




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ETON's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Arrowhead Pharmaceuticals Inc 171.02%$ 171.016 millions
Cue Biopharma Inc 166.66%$ 166.655 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________162.99%$ 162.992 millions
Cormedix Inc 156.52%$ 156.515 millions
Ataibeckley Inc 137.00%$ 136.996 millions
Pavmed Inc 135.71%$ 135.714 millions
Xilio Therapeutics Inc 131.22%$ 131.222 millions
Tenon Medical Inc 126.77%$ 126.773 millions
Sonida Senior Living Inc 122.02%$ 122.024 millions
Bridgebio Pharma Inc 120.39%$ 120.392 millions
Autolus Therapeutics Plc118.37%$ 118.367 millions
Neuraxis Inc 115.72%$ 115.717 millions
Renovorx Inc 115.40%$ 115.403 millions
Ars Pharmaceuticals Inc 114.15%$ 114.150 millions
Foghorn Therapeutics Inc 112.68%$ 112.677 millions
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions


About Eton Pharmaceuticals Inc Revenue Growth Rates (ETON), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Eton Pharmaceuticals Inc (CIK 1710340).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-26-027684
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Eton Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.